利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

22 条记录 (耗时 0.041 秒)

    Sulfonamide derivative and process for preparing the same
    3.
    发明授权
    Sulfonamide derivative and process for preparing the same 失效
    磺酰胺衍生物及其制备方法

    公开(公告)号：US5739333A

    公开(公告)日：1998-04-14

    申请号：US644847

    申请日：1996-05-09

    申请人： Koichiro Yamada ,  Kosuke Yasuda ,  Kohei Kikkawa ,  Rikako Kohno

    发明人： Koichiro Yamada ,  Kosuke Yasuda ,  Kohei Kikkawa ,  Rikako Kohno

    IPC分类号： C07D239/46 ,  C07D239/69 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D403/12 ,  C07D403/14 ,  C07D413/12

    CPC分类号： C07D239/47 ,  C07D239/69 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14

    摘要： Novel sulfonamide derivatives of the formula �I!: ##STR1## wherein Ring A and Ring B are substituted or unsubstituted monocyclic, bicyclic or tricyclic hydrocarbon, or substituted or unsubstituted heterocyclic group, Q is single bond, --O--, --S--, --SO--, --SO.sub.2 -- or --CH.sub.2 --, Y is --0--, --S-- or --NH--, Alk is lower alkylene or alkenylene, Z is --O-- or --NH --, R is substituted or unsubstituted aromatic heterocyclic or aryl, R.sup.1 is H, substituted or unsubstituted amino, substituted or unsubstituted lower alkyl, alkenyl, alkynyl, substituted or unsubstituted lower alkylthio, or alkoxy, or substituted or unsubstituted heterocyclic or aryl, or pharmaceutically acceptable salts thereof, which are useful in the prophylaxis or treatment of disorders associated with endothelin activities such as hypertension, pulmonary hypertension, renal hypertension, Raynaud disease, bronchial asthma, gastric ulcer, chronic heart failure, etc.

    摘要翻译： 式[I]的新型磺酰胺衍生物：取代或未取代的单环，双环或三环烃，或取代或未取代的杂环基，Q是单键，-O - ， - S - ， - SO-，-SO 2 - 或-CH 2 - ，Y为-O - ， - S-或-NH-，Alk为低级亚烷基或亚烯基，Z为-O-或-NH-，R为取代或未取代的芳族杂环或芳基，R 1为H，取代或未取代的 氨基，取代或未取代的低级烷基，烯基，炔基，取代或未取代的低级烷硫基或烷氧基，或取代或未取代的杂环或芳基或其药学上可接受的盐，其可用于预防或治疗与内皮素活性相关的病症，例如 作为高血压，肺动脉高压，肾性高血压，雷诺病，支气管哮喘，胃溃疡，慢性心力衰竭等。

    Arylalkylamine compound and process for preparing the same
    5.
    发明授权
    Arylalkylamine compound and process for preparing the same 有权
    芳烷基胺化合物及其制备方法

    公开(公告)号：US08362274B2

    公开(公告)日：2013-01-29

    申请号：US11597966

    申请日：2005-05-27

    申请人： Hiroshi Miyazaki ,  Junko Tsubakimoto ,  Kosuke Yasuda ,  Iwao Takamuro ,  Osamu Sakurai ,  Tetsuya Yanagida ,  Yutaka Hisada

    发明人： Hiroshi Miyazaki ,  Junko Tsubakimoto ,  Kosuke Yasuda ,  Iwao Takamuro ,  Osamu Sakurai ,  Tetsuya Yanagida ,  Yutaka Hisada

    IPC分类号： C07D295/22 ,  A61K31/40

    CPC分类号： C07D207/14 ,  C07D205/04 ,  C07D207/16 ,  C07D207/27 ,  C07D207/327 ,  C07D207/335 ,  C07D207/34 ,  C07D211/56 ,  C07D401/04 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  C07D403/06 ,  C07D403/10 ,  C07D405/12 ,  C07D409/06 ,  C07D409/12 ,  C07D417/04 ,  C07D417/06 ,  C07H17/02

    摘要： The present invention relates to an arylalkylamine compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, a process for preparing the same, and use of the above-mentioned compound as an activating compound (CaSR agonist) of a Ca sensing receptor, a pharmaceutical composition containing the above-mentioned compound as an effective ingredient, etc. The symbols in the formula represent the following meanings: Ar: optionally substituted aryl or optionally substituted heteroaryl here, the cyclic portion of the heteroaryl is bicyclic heterocyclic ring in which 5- to 6-membered monocyclic heterocyclic ring containing 1 or 2 hetero atom(s) and benzene ring are fused; R1: a group selected from the group consisting of optionally substituted cyclic hydrocarbon group, and optionally substituted heterocyclic group; n: an integer of 1 to 3; X: single bonding arm, —CH2—, —CO—, —(CH2)m—CO—, —CH(R2)—CO—, —(CH2)p—Y—(C(R3)(R4))q—CO—, —NH—CO— or —N(R5)—CO—; in the above-mentioned respective definitions of the X, the bonding arm described at the left end represents a bond with R1; m is an integer of 1 to 3; p is an integer of 0 to 2; q is an integer of 0 to 2; Y: —O— or —SO2—; R2: phenyl or lower alkyl; R3, R4: each independently represents hydrogen atom or lower alkyl; R5: lower alkyl; provided that the ring portion of the group represented by R1 is neither naphthylidine nor partially saturated group thereof, and, when X is —CH2— or —CO—, R1 is not naphthyl.

    摘要翻译： 本发明涉及由下式[I]表示的芳基烷基胺化合物或其药学上可接受的盐，其制备方法，以及使用上述化合物作为Ca感应的活化化合物（CaSR激动剂） 受体，含有上述化合物作为有效成分的药物组合物等。式中的符号表示如下含义：Ar：任选取代的芳基或任选取代的杂芳基，杂芳基的环状部分为双环杂环 含有1或2个杂原子和苯环的5-至6-元单环杂环稠合; R1：选自任选取代的环状烃基和任选取代的杂环基的基团; n：1〜3的整数; X：单键，-CH 2 - ， - CO - ， - （CH 2）m -CO-， - CH（R 2）-CO-， - （CH 2）p-Y-（C（R 3） -CO - ， - NH-CO-或-N（R 5）-CO-; 在X的上述各个定义中，左端描述的接合臂表示与R1的键; m为1〜3的整数。 p为0〜2的整数。 q为0〜2的整数; Y：-O-或-SO 2 - ; R2：苯基或低级烷基; R3，R4各自独立地表示氢原子或低级烷基; R5：低级烷基; 条件是由R1表示的基团的环部分既不是萘基也不是部分饱和的基团，并且当X是-CH 2 - 或-CO-时，R 1不是萘基。

    ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME
    7.
    发明申请
    ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME 有权
    ARYLALKYLAMINE化合物及其制备方法

    公开(公告)号：US20100249049A1

    公开(公告)日：2010-09-30

    申请号：US12776153

    申请日：2010-05-07

    申请人： Hiroshi MIYAZAKI ,  Junko TSUBAKIMOTO ,  Kosuke YASUDA ,  Iwao TAKAMURO ,  Osamu SAKURAL ,  Tetsuya YANAGIDA ,  Yataka HISADA

    发明人： Hiroshi MIYAZAKI ,  Junko TSUBAKIMOTO ,  Kosuke YASUDA ,  Iwao TAKAMURO ,  Osamu SAKURAL ,  Tetsuya YANAGIDA ,  Yataka HISADA

    IPC分类号： A61K31/7056 ,  C07D207/14 ,  A61K31/402 ,  A61P5/20 ,  C12Q1/02 ,  C07D401/04 ,  A61K31/4439 ,  C07D403/04 ,  A61K31/506 ,  A61K31/501 ,  C07D211/56 ,  A61K31/451 ,  A61K31/497 ,  C07D413/12 ,  A61K31/5377 ,  A61K31/397 ,  C07D417/06 ,  A61K31/5415 ,  A61K31/63 ,  C07H15/26

    CPC分类号： C07D207/14 ,  C07D205/04 ,  C07D207/16 ,  C07D207/27 ,  C07D207/327 ,  C07D207/335 ,  C07D207/34 ,  C07D211/56 ,  C07D401/04 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  C07D403/06 ,  C07D403/10 ,  C07D405/12 ,  C07D409/06 ,  C07D409/12 ,  C07D417/04 ,  C07D417/06 ,  C07H17/02

    摘要： The present invention relates to an arylalkylamine compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, a process for preparing the same, and use of the above-mentioned compound as an activating compound (CaSR agonist) of a Ca sensing receptor, a pharmaceutical composition containing the above-mentioned compound as an effective ingredient, etc. The symbols in the formula represent the following meanings: Ar: optionally substituted aryl or optionally substituted heteroaryl here, the cyclic portion of the heteroaryl is bicyclic heterocyclic ring in which 5- to 6-membered monocyclic heterocyclic ring containing 1 or 2 hetero atom(s) and benzene ring are fused; R1: a group selected from the group consisting of optionally substituted cyclic hydrocarbon group, and optionally substituted heterocyclic group; n: an integer of 1 to 3; X: single bonding arm, —CH2—, —CO—, —(CH2)m—CO—, —CH(R2)—CO—, —(CH2)p—Y—(C(R3)(R4))q—CO—, —NH—CO— or —N(R5)—CO—; in the above-mentioned respective definitions of the X, the bonding arm described at the left end represents a bond with R1; m is an integer of 1 to 3; p is an integer of 0 to 2; q is an integer of 0 to 2; Y: —O— or —SO2—; R2: phenyl or lower alkyl; R3, R4: each independently represents hydrogen atom or lower alkyl; R5: lower alkyl; provided that the ring portion of the group represented by R1 is neither naphthylidine nor partially saturated group thereof, and, when X is —CH2— or —CO—, R1 is not naphthyl.

    摘要翻译： 本发明涉及由下式[I]表示的芳基烷基胺化合物或其药学上可接受的盐，其制备方法，以及使用上述化合物作为Ca感应的活化化合物（CaSR激动剂） 受体，含有上述化合物作为有效成分的药物组合物等。式中的符号表示如下含义：Ar：任选取代的芳基或任选取代的杂芳基，杂芳基的环状部分为双环杂环 含有1或2个杂原子和苯环的5-至6-元单环杂环稠合; R1：选自任选取代的环状烃基和任选取代的杂环基的基团; n：1〜3的整数; X：单键，-CH 2 - ， - CO - ， - （CH 2）m -CO-， - CH（R 2）-CO-， - （CH 2）p-Y-（C（R 3） -CO - ， - NH-CO-或-N（R 5）-CO-; 在X的上述各个定义中，左端描述的接合臂表示与R1的键; m为1〜3的整数。 p为0〜2的整数。 q为0〜2的整数; Y：-O-或-SO 2 - ; R2：苯基或低级烷基; R3，R4各自独立地表示氢原子或低级烷基; R5：低级烷基; 条件是由R1表示的基团的环部分既不是萘基也不是部分饱和的基团，并且当X是-CH 2 - 或-CO-时，R 1不是萘基。